Univariate | p-value | Multivariate | p-value | ||
---|---|---|---|---|---|
Odds ratio (95 % confidence interval) | Odds ratio (95 % confidence interval) | ||||
Age at start HCV treatment (years) | 16–34 | 1 | 1 | ||
35–49 | 0.71 (0.51–0.99) | 0.04 | 0.80 (0.52–1.23) | 0.29 | |
> = 50 | 0.68 (0.43–1.07) | 0.10 | 0.58 (0.32–1.04) | 0.06 | |
Duration HCV treatment in weeks | <24 | 1 | 1 | ||
24–48 | 2.97 (2.23–3.95) | <0.0001 | 2.85 (2.0–4.05) | <0.0001 | |
>48 | 3.72 (2.77–4.99) | <0.0001 | 4.92 (3.43–7.08) | <0.0001 | |
Calendar year of starting HCV treatment | <=2003 | 0.45 (0.32–0.64) | <0.0001 | 0.41 (0.29–0.71) | 0.0008 |
2003–2005 | 0.90 (0.69–1.18) | 0.27 | 1.10 (0.78–1.59) | 0.62 | |
> = 2006 | 1 | 1 | |||
BMI | <25 | 1 | 1 | ||
> = 25 | 0.69 (0.42–1.13) | 0.14 | 1.01 (0.58–1.76) | 0.97 | |
unknown | 1.85 (1.41–2.44) | <0.0001 | 6.12 (3.99–9.38) | <0.0001 | |
Gender | Male | 1 | 0.57 | - | |
Female | 1.08 (0.84–1.38) | ||||
HIV transmission route: | MSM | 1.80 (1.28–2.53) | 0.0008 | - | |
Male injection drug us (IDU) | 1 | ||||
Female IDU | 1.26 (0.91–1.74) | 0.17 | |||
Male heterosexual | 1.03 (0.63–1.66) | 0.92 | |||
Female heterosexual | 1.07 (0.68–1.68) | 0.77 | |||
Male other/unknown | 1.18 (0.77–1.81) | 0.45 | |||
Female other/unknown | 1.48 (0.80–2.75) | 0.21 | |||
Region of origin: | Western | 1 | - | ||
Other | 1.07 (0.72–1.58) | 0.75 | |||
Unknown | 1.67 (1.09–2.56) | 0.02 | |||
HIV RNA levels at baseline (copies/ml) | <=400 | 1.00 (0.74–1.34) | 0.99 | - | |
>400 | 1 | ||||
Hepatitis B virus co-infection | No | 1 | - | ||
Yes | 1.29 (0.74–2.25) | 0.37 | |||
unknown | 0.94 (0.49–1.78) | 0.58 | |||
Nadir CD4 (cells/μl) | <200 | 1 | 1 | ||
> = 200 | 0.90 (0.72–1.14) | 0.38 | 0.80 (0.57–1.12) | 0.19 | |
CD4 at baseline (cells/μl) | 0–349 | 1 | 1 | ||
350–499 | 0.93 (0.66–1.31) | 0.68 | 0.69 (0.45–1.07) | 0.09 | |
> = 500 | 1.14 (0.84–1.54) | 0.40 | 0.94 (0.62–1.42) | 0.75 | |
missing | 0.69 (0.48–0.99) | 0.04 | 0.10 (0.05–0.19) | <0.0001 | |
HCV RNA load at baseline | <600,000 | 2.52 (1.86–3.43) | <0.0001 | 2.06 (1.38–3.06) | 0.0004 |
≥600,000 | 1 | 1 | |||
missing | 1.11 (0.85–1.44) | 0.46 | 1.41 (0.90–2.20) | 0.13 | |
HCV genotypes | 1 | 0.52 (0.32–0.87) | 0.02 | 0.27 (0.14–0.51) | <0.0001 |
1a | 0.35 (0.25–0.50) | <0.0001 | 0.25 (0.17–0.39) | <0.0001 | |
1b | 0.35 (0.23–0.53) | <0.0001 | 0.28 (0.16–0.47) | <0.0001 | |
2 & 3 | 1 | 1 | |||
4 | 0.37 (0.24–0.60) | <0.0001 | 0.32 (0.19–0.54) | <0.0001 | |
Other/unknown | 0.74 (0.55–1.02) | 0.69 | 0.70 (0.46–1.05) | 0.023 | |
APRIa score | <0.5 | 1 | 1 | ||
0.5–1.5 | 0.37 (0.28–0.50) | <0.0001 | 0.41 (0.29–0.58) | <0.0001 | |
> = 1.5 | 0.26 (0.18–0.39) | <0.0001 | 0.24 (0.15–0.39) | <0.0001 | |
unknown | 0.92 (0.68–1.25) | 0.61 | 0.61 (0.40–0.94) | 0.023 | |
Decline in haemoglobin (g/dl) | No decline | 1 | 1 | ||
<=2.5 | 1.06 (0.69–1.62) | 0.78 | 0.89 (0.52–1.51) | 0.66 | |
>2.5 | 1.93 (1.28–2.92) | 0.002 | 1.36 (0.81–2.28) | 0.24 | |
missing | 1.53 (1.08–2.19) | 0.02 | 4.66 (2.81–7.72) | <0.0001 | |
cART use: | PI | 0.62 (0.41–0.92) | 0.02 | 1.04 (0.62–1.75) | 0.87 |
Boosted PI | 0.59 (0.44–0.80) | 0.0008 | 0.61 (0.41–0.91) | 0.02 | |
NNRT | 1 | 1 | |||
PI + NNRT | 0.51 (0.27–0.97) | 0.04 | 0.65 (0.29–1.44) | 0.29 | |
No PI and/or NNRT | 0.54 (0.39–0.84) | 0.006 | 0.78 (0.44–1.39) | 0.39 | |
Start after HCV treatment | 0.86 (0.61–1.22) | 0.40 | NAb | ||
NRTI backbonea | Start after HCV treatment | 0.93 (0.65–1.33) | 0.69 | 0.96 (0.57–1.61) | 0.34 |
ABC + 3TC | 0.79 (0.54–1.15) | 0.22 | 0.74 (0.45–1.24) | 0.25 | |
AZT + 3TC | 0.53 (0.34–0.82) | 0.004 | 0.44 (0.24–0.80) | 0.007 | |
FTC + TDF | 1 | 1 | |||
TDF + 3TC | 1.17 (0.76–1.78) | 0.47 | 0.76 (0.44–1.32) | 0.33 | |
TDF + ABC | 0.81 (0.42–1.55) | 0.51 | 0.79 (0.35–1.78) | 0.57 | |
d4T + 3TC | 0.41 (0.24–0.71) | 0.001 | 0.46 (0.22–0.96) | 0.04 | |
other | 0.50 (0.34–0.73) | 0.0003 | 0.54 (0.32–0.91) | 0.02 |